FDFiona Day

Fiona Day

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fiona Day has a total of 236 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study

    by Eden Mane, Mark Tacey, Ben Loveday, Jeremy Shapiro, Michael Michael, Brett Knowles, Sue-Anne McLachlan, Rachel Wong, Rob Zielinski, Mehrdad Nikfarjam, et al.

    Introduction: The prognosis in pancreatic ductal adenocarcinoma (PDAC) remains poor with 2-year recurrence rates around 80% despite curative-intent surgery. This study evaluated factors associated with early recurrence in a contemporary, multi-center, Australasian population. A better understanding of patients at risk of early recurrence (ER) could improve selection of operative candidates. Methods: De-identified data were extracted from 23 hospitals participating in the PURPLE pancreatic cancer registry between 2016 and 2024. Clinicopathological features, treatment, recurrence patterns, and survival were examined. ER was defined as cancer recurrence within 12 months of surgery. Results: Of 3041 patients identified, 539 completed curative intent surgery. At a median follow-up of 21.8 months, 74% of resected cases had recurred. The median recurrence free survival was 14.3 months. ER occurred in 41% of patients and was associated with advanced age ( P = 0.04), worse performance status ( P < 0.01), T3–T4 stage ( P = 0.01), CA19-9 > 300 U/ml ( P < 0.01), involvement of more than two lymph nodes ( P < 0.01), lymphovascular invasion ( P = 0.01), and no neoadjuvant and/or adjuvant treatment ( P < 0.01). There was a significant association between the primary tumor location and recurrence site ( P = 0.046). The median OS of those with isolated lung (31.4 months) and locoregional (29.2 months) recurrences was longer than those with liver (21.3 months) or peritoneal (20.7 months) recurrences ( P = 0.01). The use of neoadjuvant and adjuvant therapy was associated with lower ER rates ( P < 0.01). Conclusion: A high proportion of resected PDAC patients experienced ER. Multiple pathological factors can predict ER. Primary tumor location was associated with site of recurrence. Neoadjuvant and adjuvant therapy significantly reduced ER and increased OS.


  • Open Access

    Evaluating the Efficacy of Case-Based Learning for Medical Oncology Trainees: A Systematic Review

    by Jonathon Vundum, Fiona Day

    Active learning methodologies, such as case-based learning (CBL), are widely used in undergraduate medical education. CBL is associated with high student satisfaction, knowledge acquisition and the development of critical thinking abilities. The aim of this review is to determine whether these findings are generalisable to postgraduate medical oncology trainees. A systematic review was conducted using Medline and Embase, following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. Studies were evaluated using the Critical Appraisal Skills Programme (CASP) checklist and a narrative synthesis without meta-analysis was completed to summarise findings. There is a lack of published data in this area. Three studies were eligible for review: one randomised controlled trial (RCT), one qualitative study and one educational pilot. Two studies were based in the UK and one study was based in China. In total, there were 111 participants and studies were published between 2012 and 2024. Studies universally demonstrated CBL was viewed positively by practicing doctors. Further findings included CBL being associated with perceived increases in confidence, learning and examination results. There were no reported negative aspects of CBL. All three studies had significant methodological flaws limiting the validity and reliability of stated findings. There is a lack of robust data in this field; however, the available evidence supports findings from the undergraduate setting, namely CBL is valued by trainees. Further studies are required to demonstrate whether CBL courses are feasible within speciality training programmes and whether they benefit trainee performance.


  • Open Access

    Smoking Cessation Practices in Australian Oncology Settings: A Cross‐Sectional Study of Who, How, and When

    by Alison Luk Young, Melissa McEnallay, Fiona Day, Shalini K. Vinod, Emily Stone, Sarah Morris, Elena Stefanovska, Bianca Devitt, Po Yee Yip, Craig Kukard, et al.

    Purpose: Patients who smoke tobacco during and after a cancer diagnosis have poorer health outcomes. Oncology healthcare providers (HCPs) are crucial to providing smoking cessation support. The study examined the characteristics associated with differences in HCPs’ smoking cessation practices. Methods: As part of the Care to Quit trial, a cross‐sectional survey exploring smoking cessation practices was completed by HCPs across nine cancer centers in New South Wales and Victoria, Australia. Results: One hundred and seventy‐seven HCPs completed the survey. Over half of the HCP respondents reported asking patients their smoking status, but fewer than half advised patients about the benefits of quitting, referred patients to behavioral support such as Quitline, or offered pharmacotherapy medication. All components of the “3A's” model (Ask, Advise, Act) were more likely to be completed by doctors compared to registered nurses (OR: 7.86, 95% CI: 3.64, 16.95, p p = 0.039), and those who had received smoking cessation training (OR: 3.91, 95% CI: 1.80, 8.48, p = 0.001). Multivariate analyses also identified differences in the amount of cancer‐specific advice provided between occupation type ( p p = 0.021). Conclusion: The need for smoking cessation care training in oncology continues to be apparent. Training in prescribing pharmacotherapies (for doctors) or supporting the use of pharmacotherapies (for nurses) is a particular “gap.” Differences between the roles and engagement of doctors and nurses in relation to smoking cessation care should be carefully considered when developing site‐specific models of cessation care and providing training.

  • Open Access

    A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping Smoking

    by Alison Luk Young, Melissa McEnallay, Fiona Day, Shalini K. Vinod, Emily Stone, Sarah Morris, Elena Stefanovska, Bianca Devitt, Po Yee Yip, Craig Kukard, et al.

    Aim: Smoking is a chronic relapsing condition that is under‐reported in oncology settings. People who report current smoking (CS) and those who report recently quitting smoking (RQ) should receive cessation support when they are diagnosed with cancer. The study aimed to identify whether differences exist in the smoking cessation support given to CS and RQ in oncology and what advice is given regarding the benefits of cessation.Method: A survey exploring smoking cessation practices was completed by oncology clinicians (medical, nursing, and allied health) at nine cancer centers in Australia. Data were analyzed using mixed‐effects ordinal regression modeling.Results: Across the 177 clinicians completing the survey, the reported provision of smoking cessation care was significantly higher for CS than for RQ in relation to asking about smoking status (odds ratio [OR] 3.03, p = 0.001), advice on the benefits of quitting (OR 2.86, p = 0.001), and advice to call the Quitline (OR 5.08, p < 0.001). Exploratory analyses indicated doctors and nurse specialists were four times more likely to report referring CS to a Quitline compared to RQ (OR 4.38, p = 0.001; OR 4.29, 95%, p = 0.005, respectively). The cessation benefits that clinicians most often cited to their patients was that quitting “can reduce the chance of developing treatment complications and side effects”.Conclusion: The relative lack of smoking cessation care provided to RQ in oncology suggests that the high risk of smoking relapse is not well‐recognized. Greater awareness and training are needed regarding advising RQ about the survival‐specific benefits of continuing to not smoke, offering referrals, and offering follow‐up support.


  • Open Access

    Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease

    by Fiona Day, Swetha Sridharan, Catherine Johnson, Gaik T Quah, Girish Mallesara, Mahesh Kumar, Amber‐Louise Poulter, Anthony Morrison, Andre van der Westhuizen, Allison Fraser, et al.

    Aims: Many patients diagnosed with esophageal cancer have dysphagia from their primary tumor and de novo metastatic disease. The purpose of this study was to test the safety and efficacy of nivolumab given concurrently with hypofractionated chemoradiotherapy to patients with oligometastatic and obstructing esophageal tumors.Methods: Patients were enrolled in a planned single‐arm, phase 2 clinical trial. Eligible participants had previously untreated oligometastatic (≤5 metastases on fludeoxyglucose‐18 positron emission tomography scan outside the primary tumor radiotherapy field) esophageal or gastroesophageal carcinoma, dysphagia, and Eastern Cooperative Oncology Group performance status 0–1. Treatment was with 2 weeks of concurrent hypofractionated radiotherapy (30 Gy/10#) to the primary tumor, weekly carboplatin AUC2, weekly paclitaxel 50 mg/m2, and q2weekly nivolumab 240 mg, followed by nivolumab 480 mg continuing q4weekly until disease progression or 24 months total. A single metastasis was treated with stereotactic radiotherapy (SBRT) (24 Gy/3#) in week 7.Results: Five patients were recruited before trial closure to new participants for logistical reasons. Existing participants continued treatment per protocol as a pilot study at one center. All five patients completed chemoradioimmunotherapy and SBRT. All patients derived an improvement in their dysphagia. Two patients completed 24 months of nivolumab without disease progression. Grade 3 adverse events (AEs) occurred in 3 patients, however, there were no grade 4 AEs, AEs due to SBRT, or AEs of special interest as defined by the protocol.Conclusion: Pilot results from five patients at one center found that treatment was well tolerated and effective for dysphagia relief. The efficacy of hypofractionated chemoradiotherapy with concurrent checkpoint inhibition should be tested in a multicentre study.


  • Open Access

    Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

    by Fiona Day, Swetha Sridharan, James Lynam, Craig Gedye, Catherine Johnson, Allison Fraser, Stephen R. Thompson, Michael Michael, Trevor Leong, Amitesh Roy, et al.

    Background: Oesophageal and gastrooesophageal junction (GOJ) carcinoma frequently present with dysphagia and de novo metastatic disease. There is scope to improve treatment paradigms to both address symptoms and improve survival. One method is integrating immune checkpoint inhibition with novel treatment combinations. Methods: PALEO is a single arm, phase II clinical trial in patients with previously untreated, oligometastatic or locoregionally advanced oesophageal or GOJ carcinoma and dysphagia. PALEO is sponsored by the Australasian Gastro-Intestinal Trials Group (AGITG). Participants receive 2 weeks of therapy with concurrent hypofractionated radiotherapy of 30Gy in 10 fractions to the primary tumour, weekly carboplatin AUC2, weekly paclitaxel 50 mg/m2 and durvalumab 1500 mg q4 weekly, followed by durvalumab monotherapy continuing at 1500 mg q4weekly until disease progression, unacceptable toxicity or 24 months of therapy. A single metastasis is treated with stereotactic radiotherapy of 24Gy in 3 fractions in week 7. The trial primary endpoint is the progression free survival rate at 6 months. Secondary endpoints include duration of dysphagia relief, nutritional status change, quality of life, response rate, toxicity, progression free survival and overall survival. The tertiary endpoint is prediction of outcome based on biomarkers identified from patient serial blood samples collected pre- and post-radiotherapy. Discussion: This unique investigator-initiated clinical trial is designed to simultaneously address the clinically relevant problems of dysphagia and distant disease control. The overarching aims are to improve patient nutrition, quality of life and survival with low toxicity therapy. AGITG PALEO is a multidisciplinary collaboration and will add to the understanding of the relationship between radiotherapy and the anti-tumour immune response. Trial registration: Australian and New Zealand Clinical Trials Registry: ACTRN12619001371189, registered 8 October 2019.


  • Open Access

    Psychometric properties of leadership scales for health professionals: a systematic review

    by Melissa A. Carlson, Sarah Morris, Fiona Day, Ann Dadich, Annika Ryan, Elizabeth A. Fradgley, Christine Paul

    Background: The important role of leaders in the translation of health research is acknowledged in the implementation science literature. However, the accurate measurement of leadership traits and behaviours in health professionals has not been directly addressed. This review aimed to identify whether scales which measure leadership traits and behaviours have been found to be reliable and valid for use with health professionals. Methods: A systematic review was conducted. MEDLINE, EMBASE, PsycINFO, Cochrane, CINAHL, Scopus, ABI/INFORMIT and Business Source Ultimate were searched to identify publications which reported original research testing the reliability, validity or acceptability of a leadership-related scale with health professionals. Results: Of 2814 records, a total of 39 studies met the inclusion criteria, from which 33 scales were identified as having undergone some form of psychometric testing with health professionals. The most commonly used was the Implementation Leadership Scale (n = 5) and the Multifactor Leadership Questionnaire (n = 3). Of the 33 scales, the majority of scales were validated in English speaking countries including the USA (n = 15) and Canada (n = 4), but also with some translations and use in Europe and Asia, predominantly with samples of nurses (n = 27) or allied health professionals (n = 10). Only two validation studies included physicians. Content validity and internal consistency were evident for most scales (n = 30 and 29, respectively). Only 20 of the 33 scales were found to satisfy the acceptable thresholds for good construct validity. Very limited testing occurred in relation to test-re-test reliability, responsiveness, acceptability, cross-cultural revalidation, convergent validity, discriminant validity and criterion validity. Conclusions: Seven scales may be sufficiently sound to be used with professionals, primarily with nurses. There is an absence of validation of leadership scales with regard to physicians. Given that physicians, along with nurses and allied health professionals have a leadership role in driving the implementation of evidence-based healthcare, this constitutes a clear gap in the psychometric testing of leadership scales for use in healthcare implementation research and practice. Trial registration: This review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (see Additional File 1) (PLoS Medicine. 6:e1000097, 2009) and the associated protocol has been registered with the PROSPERO International Prospective Register of Systematic Reviews (Registration Number CRD42019121544).


  • Gastrostomy dependency trends over 15 years of patients at a large tertiary referral center following the insertion of a prophylactic gastrostomy for chemoradiation for mucosal head and neck cancer

    by Allison Fraser, Cathy Odelli, Ben Britton, Mahesh Kumar, Fiona Day, Minh Thi Tieu, Chris Wratten

    Aim The routine use of prophylactic percutaneous endoscopic gastrostomy (PEG) tubes for nutrition support during radical chemoradiation for head and neck cancer has been suggested to result in PEG dependency. This research aimed to determine the rates of gastrostomy dependency at the Calvary Mater Newcastle (CMN) where PEGs are routinely used and to identify potentially modifiable risk factors. Methods All patients with head and neck cancer planned for curative chemoradiation with a prophylactic PEG inserted were included in this review. Medical records of 250 patients treated between 2000 and 2015 were examined. Results Overall, eight patients (3%) were unable to wean. At 12 months following treatment, 16 patients (6%) still required PEG tubes for feeding. A greater T extent (T4 or synchronous head and neck tumors) and number of days Nil By Mouth (NBM) remained as significant independent risk factors for PEG dependency at 12 months (Textent OR 6.96 P < .001; NBM OR 1.01 P = .004) and overall (Textent OR8.04 P = .02; NBM OR1.01 P = .001). Associations with NBM were investigated, which demonstrated that patients had less NBM days with intensity‐modulated radiation therapy (IMRT) (β‐13.3, P = .007) and seeing a speech pathologist during treatment (β‐11.9, P = .026). More NBM days were associated with tumors with greater T extent (β+22; P < .001). Conclusion The routine use of prophylactic PEGs has not resulted in significant rates of PEG dependency at the CMN. Seeing a speech pathologist during treatment and IMRT may decrease time NBM, which was identified as a potentially modifiable risk factor for PEG dependency.


  • Open Access

    Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

    by Jeremy D. Shapiro, Subotheni Thavaneswaran, Craig R. Underhill, Kristy P. Robledo, Christos S. Karapetis, Fiona L. Day, Louise M. Nott, Michael Jefford, Lorraine A. Chantrill, Nick Pavlakis, et al.